Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

South Lincolnshire, Derbyshire, Leicestershire and
10 May 2013 14:58



South Wales & Gloucestershire West Country (Devon,
27 March 2013 17:42



Northants, Oxon, Bucks, East Berks, Beds & Herts
29 April 2013 15:25



Northants, Oxon, Bucks, East Berks, Beds & Herts C
10 May 2013 12:46



Berkshire
13 February 2013 09:02


Exclusive vacancies may not be shown here, please contact Amy on +44 1494 818052 or amyp@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Amy Pearce
Account Manager
amyp@zenopa.com
+44 1494 818052

Testimonials
I contacted Zenopa directly when searching for a new job. They were extremely helpful, approachable, professional and had a wealth of knowledge and contacts enabling me to get the interviews and subse...
Tom, 2011

Abbott announces positive stent trial data

17 November 2009 00:00 in Pharmaceutical Company Product News


Abbott has revealed that a trial into its fully bioabsorbable drug eluting coronary stent produced a positive outcome.

The results, which were collated over three years across 30 patients, found that the stent successfully treated coronary artery disease and was effectively absorbed into the walls of the patients' arteries.

Those treated within the first phase of the trial experienced no blood clots and no new major adverse cardiac events between six months and three years.

Principal investigator of the trial Patrick Serruys stated: "Abbott's bioabsorbable stent has the potential to be a major breakthrough for coronary artery disease patients. The data show that patients continue to do well three years after treatment."

Meanwhile, Abbott also announced this week that it plans to acquire the rights to a product portfolio from PanGenetics BV.

This includes the company's PG110 fully-humanised antibody to Nerve Growth Factor and will expand Abbott's pain care expertise.

Other news stories from 17/11/2009

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd